Research Overview

Dr. Grier's major research focus has been the clinical management, treatment, and biology of solid tumors in children, particularly Ewing's sarcoma. His major research has been at the national level through clinical trials undertaken by the Children's Oncology Group, a consortium of cancer treatment centers across the United States, Canada, and other countries. Dr. Grier is on the steering committee of the Bone Tumor Committee. In addition to his national research positions, Dr. Grier is also part of the Pediatric Solid Tumor group at DFCI and Children's Hospital. Dr. Grier and colleagues help organize laboratory and clinical cross talk and development of lab bench to bedside clinical research. Dr. Grier is also involved in cancer survivor studies that focus on the late effects of chemotherapy, studies which are led by Dr. Lisa Diller at the David B. Perini Jr. Quality of Life Clinic at DFCI. In addition, he participates in a study of the best application of palliative care through work with the Pediatric Advanced Care Team, led by Dr. Joanne Wolfe.

Research Background

Holcombe Grier received his MD from the University of Pennsylvania. He trained in pediatrics, internal medicine, and infectious disease at the University of North Carolina. He was a fellow in pediatric hematology/oncology at Children’s Hospital and the Dana-Farber Cancer Institute. He is a past president of the American Society of Pediatric Hematology/Oncology. He received the Charles A. Janeway Award for Excellence in Clinical Teaching of Children's Hospital House Staff in 1992, a Harvard Medical School Faculty Prize for Excellence in Teaching [Years III and IV] in 2008 and a Harvard Medical School Community Service award in 2009.

Education

Undergraduate School

Trinity College
1972 Hartford CT

Medical School

University of Pennsylvania School of Medicine
1976 Philadelphia PA

Internship

North Carolina Memorial Hospital
1977 Chapel Hill NC

Residency

North Carolina Memorial Hospital
1980 Chapel Holl NC

Fellowship

Pediatric Hematology-Oncology Boston Children's Hospital / Dana-Farber Cancer Institute
1983 Boston MA

Publications

  1. Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children's Oncology Group Bone Tumor Committee Consensus Statement. J Natl Compr Canc Netw. 2024 12 27; 23(1). View Abstract
  2. In Memoriam: Sharon B. Murphy, MD (1943-2023). Pediatr Blood Cancer. 2024 Feb; 71(2):e30797. View Abstract
  3. Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031. J Clin Oncol. 2023 10 20; 41(30):4724-4728. View Abstract
  4. Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023 02 01; 115(2):337-346. View Abstract
  5. Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report. J Clin Oncol. 2021 12 20; 39(36):4029-4038. View Abstract
  6. Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2021 02; 68(2):e28807. View Abstract
  7. Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology Group. Cardiooncology. 2019; 5:15. View Abstract
  8. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019 12 01; 37(34):3192-3202. View Abstract
  9. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur J Cancer. 2019 03; 109:36-50. View Abstract
  10. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer. 2018 05 01; 124(9):1973-1981. View Abstract
  11. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood Cancer. 2018 04; 65(4). View Abstract
  12. Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1286-1294. View Abstract
  13. Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation. PLoS One. 2017; 12(7):e0181204. View Abstract
  14. Completion of Therapy Talk. J Oncol Pract. 2016 09; 12(9):769-71. View Abstract
  15. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct; 17(10):1396-1408. View Abstract
  16. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8. View Abstract
  17. Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 10; 63(10):1771-9. View Abstract
  18. Local Control Modality and Outcome for Ewing Sarcoma of the Femur: A Report From the Children's Oncology Group. Ann Surg Oncol. 2016 10; 23(11):3541-3547. View Abstract
  19. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50. View Abstract
  20. Age, Tumor Characteristics, and Treatment Regimen as Event Predictors in Ewing: A Children's Oncology Group Report. Sarcoma. 2015; 2015:927123. View Abstract
  21. Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2016 Jan; 63(1):54-61. View Abstract
  22. Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer. 2016 Jan; 63(1):47-53. View Abstract
  23. Myogenic tumors in nevoid Basal cell carcinoma syndrome. J Pediatr Hematol Oncol. 2015 Mar; 37(2):147-9. View Abstract
  24. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer. 2015 Feb 01; 121(3):467-75. View Abstract
  25. Comparing oxazaphosphorines for treating Ewing sarcoma: is the answer important two decades later? J Clin Oncol. 2014 Aug 10; 32(23):2401-2. View Abstract
  26. HER-2 expression is not prognostic in osteosarcoma; a Children's Oncology Group prospective biology study. Pediatr Blood Cancer. 2014 Sep; 61(9):1558-64. View Abstract
  27. Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. J Pediatr Hematol Oncol. 2014 Apr; 36(3):237-40. View Abstract
  28. Mutations in Hedgehog pathway genes in fetal rhabdomyomas. J Pathol. 2013 Sep; 231(1):44-52. View Abstract
  29. Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study. Pediatr Blood Cancer. 2013 Jul; 60(7):1108-12. View Abstract
  30. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Nov 20; 30(33):4148-54. View Abstract
  31. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol. 2012 Jul 10; 30(20):2545-51. View Abstract
  32. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. Cancer. 2012 Sep 15; 118(18):4597-605. View Abstract
  33. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. View Abstract
  34. Parents' roles in decision making for children with cancer in the first year of cancer treatment. J Clin Oncol. 2011 May 20; 29(15):2085-90. View Abstract
  35. Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012 Feb; 58(2):181-4. View Abstract
  36. Training program in cancer and blood diseases: Pediatric Hematology/Oncology Fellowship Program, Children's Hospital Boston/Dana-Farber Cancer Institute. Am J Hematol. 2010 Oct; 85(10):793-4. View Abstract
  37. p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Pediatr Dev Pathol. 2010 May-Jun; 13(3):218-24. View Abstract
  38. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010 Jul; 11(7):670-8. View Abstract
  39. Ovarian tissue autologous transplantation to the upper extremity for girls receiving abdominal/pelvic radiation: 20-year follow-up of reproductive endocrine function. J Pediatr Adolesc Gynecol. 2010 Apr; 23(2):107-10. View Abstract
  40. Sinonasal and laryngeal carcinoma in children: correlation of imaging characteristics with clinicopathologic and cytogenetic features. AJNR Am J Neuroradiol. 2010 Feb; 31(2):257-61. View Abstract
  41. Primary pediatric intraspinal sarcomas. Report of 3 cases. J Neurosurg Pediatr. 2009 Sep; 4(3):222-9. View Abstract
  42. Peace of mind and sense of purpose as core existential issues among parents of children with cancer. Arch Pediatr Adolesc Med. 2009 Jun; 163(6):519-24. View Abstract
  43. Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. Nat Rev Clin Oncol. 2009 May; 6(5):251-3. View Abstract
  44. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009 May 20; 27(15):2536-41. View Abstract
  45. Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Mar; 52(3):324-7. View Abstract
  46. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer. 2009 Mar; 52(3):387-91. View Abstract
  47. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2008 Sep; 51(3):334-8. View Abstract
  48. Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. J Pediatr Hematol Oncol. 2008 Sep; 30(9):716-8. View Abstract
  49. Imaging guidelines for children with Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2008 Aug; 51(2):163-70. View Abstract
  50. Peace of mind and sense of purpose as core existential issues among parents of children with cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):9518. View Abstract
  51. Easing of suffering in children with cancer at the end of life: is care changing? J Clin Oncol. 2008 Apr 01; 26(10):1717-23. View Abstract
  52. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008 Feb 01; 26(4):633-8. View Abstract
  53. Hope and prognostic disclosure. J Clin Oncol. 2007 Dec 10; 25(35):5636-42. View Abstract
  54. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. Pediatr Blood Cancer. 2007 Dec; 49(7):894-900. View Abstract
  55. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 2007 May 20; 25(15):2057-62. View Abstract
  56. Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol. 2007 May; 29(5):351-2. View Abstract
  57. Understanding of prognosis among parents of children with cancer: parental optimism and the parent-physician interaction. J Clin Oncol. 2007 Apr 10; 25(11):1357-62. View Abstract
  58. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol. 2007 Feb 10; 25(5):501-6. View Abstract
  59. Telling children and adolescents about their cancer diagnosis: Cross-cultural comparisons between pediatric oncologists in the US and Japan. Psychooncology. 2007 Jan; 16(1):60-8. View Abstract
  60. Communication about prognosis between parents and physicians of children with cancer: parent preferences and the impact of prognostic information. J Clin Oncol. 2006 Nov 20; 24(33):5265-70. View Abstract
  61. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood. 2007 Jan 01; 109(1):46-51. View Abstract
  62. Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. J Clin Oncol. 2006 Aug 20; 24(24):3838-43. View Abstract
  63. Understanding of prognosis among parents of children with cancer: Parental optimism and the role of the parent-physician interaction. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6033. View Abstract
  64. Mucoepidermoid carcinoma of the parotid gland in children: A 10-year experience. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):375-80. View Abstract
  65. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457--a report from the Children's Oncology Group. J Clin Oncol. 2006 Jan 01; 24(1):152-9. View Abstract
  66. Parent and physician perspectives on quality of care at the end of life in children with cancer. J Clin Oncol. 2005 Dec 20; 23(36):9155-61. View Abstract
  67. Therapy-related myelodysplasia/ leukemia (t-MDS/AML) following treatment of children with Ewing sarcoma and primitive neuroectodermal tumor of bone (PNET). J Clin Oncol. 2005 Jun; 23(16_suppl):8514. View Abstract
  68. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005 Mar 20; 23(9):2004-11. View Abstract
  69. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. J Clin Oncol. 2005 Jun 20; 23(18):4031-8. View Abstract
  70. Factors associated with the quality of care at the end of life in children with cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8529. View Abstract
  71. P9754 therapeutic intensification in non-metastatic osteosarcoma: A COG trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8514. View Abstract
  72. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Mar 15; 58(4):1208-14. View Abstract
  73. The Day One Talk. J Clin Oncol. 2004 Feb 01; 22(3):563-6. View Abstract
  74. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003 Dec; 25(12):934-40. View Abstract
  75. The role of chromosomal translocation (15;19) in the carcinoma of the upper aerodigestive tract in children. Otolaryngol Head Neck Surg. 2003 Dec; 129(6):698-704. View Abstract
  76. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 2003 Nov 15; 9(15):5442-53. View Abstract
  77. Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg. 2003 Oct; 238(4):563-7; discussion 567-8. View Abstract
  78. Involvement of the gonadal germinal epithelium during sex reversal and seasonal testicular cycling in the protogynous swamp eel, Synbranchus marmoratus Bloch 1795 (Teleostei, Synbranchidae). J Morphol. 2003 Jul; 257(1):107-26. View Abstract
  79. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003 Apr 15; 21(8):1574-80. View Abstract
  80. Ultrastructure of the testis in Synbranchus marmoratus (Teleostei, Synbranchidae): the germinal compartment. Tissue Cell. 2003 Apr; 35(2):121-32. View Abstract
  81. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003 Feb 20; 348(8):694-701. View Abstract
  82. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res. 2003 Feb; 9(2):837-44. View Abstract
  83. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003 Jan 15; 63(2):304-7. View Abstract
  84. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol. 2002 Dec; 24(9):722-6. View Abstract
  85. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics. 2002 Feb; 109(2):E37. View Abstract
  86. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002 Jan 15; 20(2):426-33. View Abstract
  87. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. Obstet Gynecol. 2001 Nov; 98(5 Pt 2):929-31. View Abstract
  88. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol. 2001 Oct 15; 19(20):4058-64. View Abstract
  89. Aggressive multimodal treatment of pleuropulmonary blastoma. Ann Thorac Surg. 2001 Sep; 72(3):939-42. View Abstract
  90. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma? Semin Pediatr Surg. 2001 Aug; 10(3):146-52. View Abstract
  91. Ewing's sarcoma/primitive neuroectodermal tumor of the chest wall. Semin Pediatr Surg. 2001 Aug; 10(3):153-60. View Abstract
  92. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group Trial. J Pediatr Hematol Oncol. 2001 Aug-Sep; 23(6):340-8. View Abstract
  93. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001 Feb 01; 91(3):613-21. View Abstract
  94. Understanding of prognosis among parents of children who died of cancer: impact on treatment goals and integration of palliative care. JAMA. 2000 Nov 15; 284(19):2469-75. View Abstract
  95. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000 Jul; 18(13):2567-75. View Abstract
  96. Ewing sarcoma of the rib: results of an intergroup study with analysis of outcome by timing of resection. J Thorac Cardiovasc Surg. 2000 Jun; 119(6):1154-61. View Abstract
  97. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol. 2000 Jun; 18(12):2427-34. View Abstract
  98. Symptoms and suffering at the end of life in children with cancer. N Engl J Med. 2000 Feb 03; 342(5):326-33. View Abstract
  99. Soft tissue sarcoma: apples, oranges, and passion fruit. J Clin Oncol. 1999 Dec; 17(12):3695-6. View Abstract
  100. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):486-93. View Abstract
  101. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999 Nov; 17(11):3487-93. View Abstract
  102. Does debulking improve survival rate in advanced-stage retroperitoneal embryonal rhabdomyosarcoma? J Pediatr Surg. 1999 May; 34(5):736-41; discussion 741-2. View Abstract
  103. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998 Nov; 153(5):1451-8. View Abstract
  104. Congenital fibrosarcoma of the upper extremity. Plast Reconstr Surg. 1998 Sep; 102(4):1158-62. View Abstract
  105. Combination chemotherapy using vinblastine and methotrexate for the treatment of progressive desmoid tumor in children. J Clin Oncol. 1998 Sep; 16(9):3021-7. View Abstract
  106. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2494-9. View Abstract
  107. Primary malignant epithelial tumors of the liver in children: a study of DNA content and oncogene expression. Pediatr Dev Pathol. 1998 Jul-Aug; 1(4):270-80. View Abstract
  108. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet. 1998 Jan 15; 100(2):106-10. View Abstract
  109. Childhood soft tissue sarcoma: a 20-year experience. J Pediatr. 1997 Oct; 131(4):603-7. View Abstract
  110. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors. Pediatr Clin North Am. 1997 Aug; 44(4):991-1004. View Abstract
  111. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997 Feb; 15(2):583-8. View Abstract
  112. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 1996 Nov; 18(4):352-61. View Abstract
  113. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. J Pediatr. 1996 Nov; 129(5):722-8. View Abstract
  114. Treatment of endodermal sinus tumor in children using a regimen that lacks bleomycin. Med Pediatr Oncol. 1996 Aug; 27(2):69-73. View Abstract
  115. Regional anesthesia for pain associated with terminal pediatric malignancy. Pain. 1996 Apr; 65(1):63-69. View Abstract
  116. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J Clin Apher. 1996; 11(4):195-203. View Abstract
  117. Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Pain. 1995 Nov; 63(2):271-275. View Abstract
  118. Treatment of patients with acute myelogenous leukemia: review of clinical trials of the past decade. J Pediatr Hematol Oncol. 1995 Aug; 17(3):185-97. View Abstract
  119. Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer. 1995 Jun 15; 75(12):2966-70. View Abstract
  120. A 10-year experience of pediatric brachytherapy. Int J Radiat Oncol Biol Phys. 1995 May 15; 32(2):451-5. View Abstract
  121. Control of severe pain in children with terminal malignancy. J Pediatr. 1995 Apr; 126(4):653-7. View Abstract
  122. A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study. Invest New Drugs. 1995; 13(3):211-6. View Abstract
  123. Chest wall tumors in infants and children. Semin Pediatr Surg. 1994 Nov; 3(4):267-76. View Abstract
  124. Percutaneous biopsy of peripheral primitive neuroectodermal tumors and Ewing's sarcomas for cytogenetic analysis. AJR Am J Roentgenol. 1994 May; 162(5):1141-2. View Abstract
  125. Ewing's sarcoma--routine diagnostic utilization of MIC2 analysis: a Pediatric Oncology Group/Children's Cancer Group Intergroup Study. Hum Pathol. 1994 Mar; 25(3):304-7. View Abstract
  126. Malignant small round cell tumor (Ewing's-PNET) of the chest wall in children. J Pediatr Surg. 1994 Feb; 29(2):179-84; discussion 184-5. View Abstract
  127. Fibrosarcoma in infants and children. Application of new techniques. Am J Surg Pathol. 1994 Jan; 18(1):14-24. View Abstract
  128. Detection of the (11;22)(q24;q12) translocation of Ewing's sarcoma and peripheral neuroectodermal tumor by reverse transcription polymerase chain reaction. Am J Pathol. 1993 Nov; 143(5):1294-300. View Abstract
  129. A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study. Invest New Drugs. 1993 Nov; 11(4):309-12. View Abstract
  130. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study. Cancer. 1993 Sep 01; 72(5):1790-4. View Abstract
  131. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics. 1993 Sep; 92(3):358-64. View Abstract
  132. Posterior mediastinal masses. J Pediatr Surg. 1993 Feb; 28(2):172-6. View Abstract
  133. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol. 1993 Jan; 11(1):84-90. View Abstract
  134. Barbiturates in the care of the terminally ill. N Engl J Med. 1992 Dec 03; 327(23):1678-82. View Abstract
  135. Evaluation of CHIP (iproplatin) in recurrent pediatric malignant solid tumors. A phase II study (Pediatric Oncology Group). Invest New Drugs. 1992 Jul; 10(2):93-6. View Abstract
  136. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. Leukemia. 1992; 6 Suppl 2:48-51. View Abstract
  137. Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy? J Pediatr Surg. 1991 Sep; 26(9):1113-7; discussion 1117-8. View Abstract
  138. Stage IV neuroblastoma in infants. Long-term survival. Cancer. 1991 Mar 15; 67(6):1493-7. View Abstract
  139. Cancer in relatives of survivors of childhood sarcoma. Cancer. 1991 Mar 01; 67(5):1467-9. View Abstract
  140. Consistent cytogenetic aberrations in hepatoblastoma: a common pathway of genetic alterations in embryonal liver and skeletal muscle malignancies? Genes Chromosomes Cancer. 1991 Jan; 3(1):37-43. View Abstract
  141. Undifferentiated (embryonal) sarcoma of the liver. Clinical and pathologic study of 16 cases with emphasis on immunohistochemical features. Am J Surg Pathol. 1991 Jan; 15(1):1-16. View Abstract
  142. Paratesticular rhabdomyosarcoma: results of therapy in 18 cases. J Urol. 1990 Dec; 144(6):1450-3. View Abstract
  143. Celiac plexus blockade for a 3-year-old boy with hepatoblastoma and refractory pain. Pediatrics. 1990 Nov; 86(5):779-81. View Abstract
  144. Ewing's sarcoma of bone. Curr Opin Oncol. 1990 Jun; 2(3):491-4. View Abstract
  145. myc gene amplification and expression in primary human neuroblastoma. Cancer Res. 1990 Mar 01; 50(5):1459-63. View Abstract
  146. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Blood Transfus. 1990; 33:193-7. View Abstract
  147. Chest wall tumors in infancy and childhood. Cancer. 1989 Feb 15; 63(4):774-85. View Abstract
  148. Caudal epidural morphine analgesia for an infant with advanced neuroblastoma: report of a case. Pain. 1989 Feb; 36(2):219-223. View Abstract
  149. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989 Jan; 7(1):126-31. View Abstract
  150. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. Cancer Chemother Pharmacol. 1989; 24(2):123-7. View Abstract
  151. Prognostic factors in childhood acute myelogenous leukemia. J Clin Oncol. 1987 Jul; 5(7):1026-32. View Abstract
  152. Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors. Haematol Blood Transfus. 1987; 30:88-92. View Abstract
  153. Cytogenetic evidence for involvement of erythroid progenitors in a child with therapy linked myelodysplasia. Br J Haematol. 1986 Nov; 64(3):513-9. View Abstract
  154. The surgical management of fungal pulmonary infections in children with acute myelogenous leukemia. J Pediatr Surg. 1985 Dec; 20(6):840-4. View Abstract
  155. Chemotherapy for inoperable infantile fibrosarcoma. Cancer. 1985 Oct 01; 56(7):1507-10. View Abstract
  156. Acute nonlymphocytic leukemia. Pediatr Clin North Am. 1985 Jun; 32(3):653-68. View Abstract
  157. Detection of leukemia-related karyotypes in granulocyte/macrophage colonies from a patient with acute myelomonocytic leukemia. N Engl J Med. 1983 Jun 02; 308(22):1324-8. View Abstract
  158. Estradiol binding capacity in the cryptorchid rat testis. Endocrinology. 1977 Sep; 101(3):975-83. View Abstract
  159. Gonadotropin binding factor(s). Extraction of high affinity gonadotropin binding sites from rat testis and partial characterization of their interaction with human follitropin, lutropin, and choriogonadotropin. J Biol Chem. 1976 Aug 25; 251(16):4947-57. View Abstract

Contact Holcombe E. Grier

Print Profile